Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion, adding clinical-stage oral NLRP3 inhibitors to its pipeline. The deal consolidates Lilly’s push into inflammation and immunology, pairing Ventyx’s VTX3232 program—tested in obesity, Parkinson’s and pericarditis—with Lilly’s metabolic and neurodegeneration franchises. Lilly said the acquisition strengthens its oral immune-drug capabilities and positions the company to expand into cardiometabolic and neurological indications. Ventyx reported data showing reductions in inflammatory biomarkers and metabolic signals when VTX3232 was tested in obesity cohorts; the asset also has programs in Parkinson’s disease and pericarditis. Lilly framed the purchase as strategic vertical integration to accelerate development of oral therapies that block NLRP3-driven inflammation, a mechanism that spans multiple chronic diseases. Financial terms and near-term regulatory plans center on folding Ventyx programs into Lilly’s development engine.